Viracta Therapeutics: Q3 Earnings Insights

Viracta Therapeutics (NASDAQ:VIRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:30 AM. Here’s what…

byBenzinga Insights

November 9, 2023

1 minute read

Viracta Therapeutics (NASDAQ:VIRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Viracta Therapeutics missed estimated earnings by 10.0%, reporting an EPS of $-0.33 versus an estimate of $-0.3.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.04 which was followed by a 7.8% drop in the share price the next day.

** Listen to the earnings announcement yourself by clicking here. **

To track all earnings releases for Viracta Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Earnings

IPG Photonics’s Earnings: A Preview

By Benzinga Insights

October 30, 11:01 AM

IPG Photonics (NASDAQ:IPGP) is set to give its latest quarterly earnings report on Tuesday, 2023-10-31. Here’s what investors…

IPGP

Earnings

Cognyte Software’s Earnings Outlook

By Benzinga Insights

September 11, 10:01 AM

Cognyte Software (NASDAQ:CGNT) is set to give its latest quarterly earnings report on Tuesday, 2023-09-12. Here’s what investors…

CGNT

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

By Jelena Martinovic

May 16, 11:25 AM

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB